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Abstract  
Introduction: 
Lenvatinib (LEN) is a multi-kinase anti-angiogenic drug recently approved in several cancers. LEN is not 
easily manageable due to its complex safety profile. Proteinuria and renal failure (RF) were reported among 
the most frequent LEN-induced adverse events (AEs), often leading to discontinuations or dose 
modifications. Understanding the pathogenesis of these AEs could ameliorate the management of LEN-
induced renal toxicity.    
 
Areas covered:  
We present two cases of LEN-induced renal failure (LIRF) with different pathogenesis. 1) LIRF with severe 
proteinuria in a man treated for a metastatic papillary thyroid carcinoma. Kidney biopsy showed a 
glomerular damage secondary to LEN, having excluded other causes of RF.  2) LIRF without proteinuria in a 
woman with metastatic adenoid cystic carcinoma of minor salivary gland. A tubulointerstitial nephropathy 
was supposed by clinical evaluation and laboratory tests. Effective management was obtained by oral 
steroids without interrupting LEN. 
 
Expert opinion: 
The case 1 presented for the first time the histological picture of LIRF with a classical glomerular damage 
leading to secondary proteinuria and tubular failure. Case 2 showed an alternative LIRF pattern of likely 
tubulointerstitial injury without proteinuria. These reports reflect two sides of the same coin, both to be 
considered in case of LIRF.  
 
 
KEYWORDS:  
Antiangiogenic, lenvatinib, nephropathy, proteinuria, renal failure, salivary gland cancer, thyroid cancer, 
toxicity, VEGF, VEGFR 
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Article Highlights: 
1. Proteinuria is recognized as a class side effect among antiangiogenic drugs, such as lenvatinib 
2. Proteinuria  often leads to lenvatinib interruptions and/or dose modifications 
3. Lenvatinib-induced renal failure (LIRF)  might be associated with glomerular damage, with 
secondary proteinuria and tubular injury  
4. A primary tubulointerstitial injury may be identified as alternative pattern of LIRF without 
proteinuria development 
5. Low-dose steroids can be used to manage the primary  non-glomerular  lenvatinib-induced damage 
without requiring lenvatinib interruption or discontinuation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
 
 
1. INTRODUCTION 
Lenvatinib (Lenvima®, LEN) is an orally bioavailable  multitarget tyrosine kinase inhibitor (TKI), acting on 
VEGFR, FGFR, PDGFR-α, KIT and RET. [1] 
To date, LEN is licensed for advanced progressive radioactive-iodine (RAI) refractory differentiated thyroid 
cancer (DTC) patients [2] .  It has also been approved by Food and Drug Administration (FDA) and European 
Medicines Agency (EMA), in combination with everolimus, as second-line in advanced renal cell carcinoma 
(RCC)[3]. Recently, FDA has recently approved LEN as first-line therapy in advanced hepatocellular 
carcinoma (HCC) considering the results of non-inferiority (versus sorafenib) phase III trial (REFLECT) [4]. 
Moreover, LEN has already been studied as monotherapy [5] and in combination with immunotherapy 
(pembrolizumab) [6] in renal cell carcinoma, in metastatic or recurrent endometrial cancer (EC) [5] and in 
anaplastic thyroid cancer (ATC) [7].  The results of a single-Institution phase II study with LEN in advanced 
adenoid cystic carcinoma (ACC) of salivary glands will be published in the near future since recruitment has 
already been completed [8]. Table 1 summarized all ongoing clinical trials evaluating LEN in several other 
malignancies. 
In brief, in the era of targeted therapies, LEN is is one of the most promising targeted agents with multiple 
opportunities of application in the clinical practice.  
 
 
2. CASE REPORTS 
Here, we report two cases of LEN-induced renal failure (LIRF).   
These two reports gave us the opportunity to review, understand and discuss pathogenesis of LIRF in order 
to better manage this toxicity. Both cases were reported to the Italian network of pharmacovigilance [9]. 
Informed consent forms were collected.   
 
2.1 CASE 1 
2.1.1 CLINICAL HISTORY 
In 1998 a papillary thyroid carcinoma was diagnosed in a 44-year-old man, with arterial hypertension (AH) 
as only comorbidity (AH managed by doxazosin  2 mg, atenolol 25 mg and chlorthalidone 6.25 mg per day). 
He underwent total thyroidectomy (stage pT2a, cN0 cM0 according to seventh edition of AJCC TNM), post-
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operative thyroid stimulating hormone (TSH) suppression by oral levothyroxine and one course (80 mCi) of 
RAI. During follow-up (2004), despite a negative whole body 131RAI scan (131RAI -WBS), serum thyroglobulin 
progressively increased, suggesting the presence of micrometastatic dissemination,  so a new course of 
131RAI (200 mCi) was administered. In 2007 a right selective neck dissection was performed due to 
locoregional relapse (3 out of 30 lymph nodes were metastatic). Two years later (2009), 131RAI-WBS was 
negative while both 18FluoroDesoxyGlucose (FDG)-Positron Emission Tomography (PET) and 68Ga DOTATOC 
[68gallium bound to DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and octreotide] PET 
showed a locoregional and distant (mediastinal lymph nodes and right lung) disease recurrence. Based on 
these characteristics, disease was considered as RAI-resistant and four cycles of 68Ga-DOTATOC were 
administered (cumulative dose 403 mCi) with substantial stable disease (SD). Due to progression of disease 
(PD) with concomitant negative 68Ga DOTATOC PET scan, patient was treated with sorafenib from 
September 2010 until PD in August 2011. Further surgery (left selective neck dissection) was performed in 
December 2011 due to lymph nodal progression. In April 2012 FDG-PET showed bilateral pulmonary PD, 
confirmed by a chest CT scan. Therefore, in September 2012 patient, aged 58 years, was referred to our 
Institution for a second-line systemic therapy. Patient was enrolled within SELECT trial [2] and  received LEN 
at daily dose of 24 mg. At baseline, patient performance status (PS) was good (Eastern Cooperative 
Oncology Group, ECOG PS 1) and blood pressure was well balanced by his usual anti-hypertensive therapy. 
Pre-treatment laboratory (lab) tests showed mild [grade 1 according to Common Terminology Criteria for 
Adverse Events (CTCAE) 4.03] abnormalities of serum creatinine (1.65 mg/dl, range 0.10-1.20) and 
proteinuria (1+ at urine dipstick). Proteinuria was managed as per protocol: if proteinuria was ≥2+ at urine 
dipstick, a 24-hour proteinuria was evaluated within 72 hours without LEN interruption; in case of 
proteinuria lower than 1 g/24h (≤ grade 1 CTCAE) the drug was continued, otherwise LEN was discontinued 
until toxicity was resolved to grade 0-1 or baseline and reduced at lower level dose when resumed. Figure 1 
summarized a time-dependent overview of LEN management (e.g. all temporary discontinuations and dose 
reductions to 20, 14 and 10 mg/day at 6th, 10th and 36th treatment month, respectively) based on the 
evolution of serum creatinine and proteinuria. Concomitantly, a persistent disease control was achieved 
after a partial remission, occurred as best response at 2nd month of LEN course. Considering this  significant 
clinical benefit and that baseline proteinuria was abnormal (grade 1) remaining stable (2+ at urine dipstick) 
for one year of treatment (with no further AEs), an agreement with study Sponsor (Eisai) was established. 
This consisted of performing 24-hour proteinuria only in case of 3+ at urine dipstick. At the fourth year of 
LEN, proteinuria worsened (G3, >3.5g/24h according to CTCAE), with significant increase of AH (G3, 160/80 
mmHg) and serum creatinine (G1, 1.9 mg/dl), so LEN was interrupted and patient was hospitalized.  Due to 
the persistence of lab tests abnormalities after 10 days of LEN discontinuation (half-life of LEN is 
approximately 28 hours), a kidney biopsy was performed in order to exclude all possible other causes of 
renal failure (RF). So, a complex pattern of drug-related glomerular, tubulointerstitial, and vascular renal 
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injury was diagnosed (Figures 2 and 3). Histological details will be reported in the next paragraph. After the 
start of angiotensin converting enzyme (ACE) inhibitor, blood pressure values were normalized while 
proteinuria (G1) and serum creatinine significantly decreased (G1, 1.68 mg/dl) within further 4 weeks.   
LEN was definitively stopped and patient went on clinical and radiological follow-up every 4-6 months. 
Following lab tests showed chronic kidney damage (serum creatinine ranging from 1.4 to 1.6 mg/dl and 
proteinuria 1+ to 2+ at urine dipstick).  
 
2.1.2 HISTOLOGICAL FINDINGS  
For the histological analysis, kidney biopsy was fixed in 10% buffered formalin and embedded in paraffin. 
Specific staining for renal tissue was performed. A second specimen was snap-frozen and used for immune-
fluorescence analysis. A third sample (5 mm) was fixed in 2.5% glutaraldehyde, embedded in resin and 
reserved for electron microscopy. Semi-thin and thin sections were cut and stained using conventional 
methods. Tissues were then examined by transmission electron microscopy (Zeiss EM109 electron 
microscope).   
Light microscopy examination revealed a huge number (n=24) of glomeruli, whose 45% (n=11) were 
globally sclerotic. The remaining glomeruli (n=13) showed mesangial hypercellularity and increase of 
mesangial matrix. In one glomerulus, segmental features of mesangiolysis were observed. Capillary basal 
membranes were thickened with double contours (Figure 2). Moreover, endothelial ipertrophy and 
swelling, intimal edema and focal sub-endothelial necrosis characterized the arteriolar narrowing. No 
inflammatory reaction was detected in the vessels wall. The interstitial component showed fibrosis and 
tubular atrophy.  
Immune-fluorescence analysis revealed weak focal and segmental staining for immunoglobulins and 
complement along the capillary basal membrane.  
Ultrastructural examination (Figure 3) showed focal glomerular sclerosis, focal podocyte foot process 
effacement and rare electron dense deposits with subendothelial and intramembranous localization.  
The diagnosis concluded for a drug-induced renal damage characterized by tubulointerstitial vascular 
necrotic injury and endothelial alterations suggesting for a thrombotic microangiopathy (TMA)-like pattern 
with ultrastructural evidence of podocytes foot process effacement.  
 
2.2 CASE 2 
2.2.1 CLINICAL HISTORY 
In 2015 a 59-year-old woman, without significant cardiologic or pneumologic comorbidities (no 
conocomitant medications at baseline), started her clinical history suffering of steroid-resistant mild 
dyspnea. A fiber optic bronchoscopy showed a subtotal occlusion of the medium third part of the trachea 
Ac
ce
pte
d M
an
us
cri
pt
by neoplastic nodules protruding from the anterior and right lateral walls, which widely infiltrated the 
carina. Laser photocoagulative treatment and endoscopic excision of the tumor lesions allowed a prompt 
airways recanalization. The histopathological exam showed an adenoid cystic carcinoma (ACC) with 
cribriform and solid features, originating from the minor salivary glands of the trachea. 
A whole body computed tomography (CT) scan showed enlarged mediastinal (upper carinal and pre-carinal 
regions) lymph nodes obstructing the trachea from its anterior wall. Multiple  liver metastases (maximum 
diameter 35 mm) were observed as well. 
Two courses of palliative chemotherapy with cisplatin and doxorubicin was administered every 3 weeks 
from May to June 2015. Endoscopic assessments showed  stable disease at the tracheal level and a 
multidisciplinary team consultation excluded the feasibility of a local irradiation. However, a CT scan 
revealed disease progression in the liver.  Therefore, chemotherapy was discontinued and patient was 
referred to our Institution for enrollment within a phase II trial with LEN in   recurrent and/or metastatic 
ACC[8]. On July 2015, patient with ECOG PS 0, no symptoms and normal baseline blood/urinary analyses, 
received the first course of LEN at 24 mg daily. After only one month, LEN was temporarily discontinued for 
15 days and then resumed at 20 mg daily due to G3 gastrointestinal toxicity. During LEN trial, disease 
revaluations (whole body CT scan and bronchoscopy)  performed one every 8 weeks showed a SD both at 
local and distant sites.   
In October 2016 (15 months from the LEN start),  lab tests showed a progressive impairment in renal 
function tests: serum creatinine values increased from 0.95 mg/dl (range: 0.1-0.9 mg/dl) to 1.34 mg/dl in 
November 2016 until a maximum value of 2.81 mg/dl in December 2016, when blood urea nitrogen (BUN) 
was 155 mg/dl (range: 15-45 mg/dl) and no associated blood electrolytes imbalances were observed. In 
December 2016, urine exams (including creatinine clearance/24 hours) excluded any grade of proteinuria. 
This acute RF improved very rapidly (after only 2 LEN days off, creatinine was 1.27 mg/dl and BUN 53 
mg/dl) thanks to intravenous hydration and temporary LEN interruption (lasting for 10 days). After one 
month of LEN, which was resumed at reduced daily dose of 14 mg, a new increase of serum creatinine (1.63 
mg/dl) and BUN (91 mg/dl) occurred, without any other laboratory abnormalities. Primary glomerular 
damage was excluded because proteinuria and albuminuria were lower than 1 g/24h and 20 mg in spot 
urinalysis, respectively. At urine exam amorphous sediment and no cylindruria were also observed. Normal  
blood count, coagulation tests, lactate dehydrogenase and haptoglobin excluded hemolytic uremic 
syndrome and other thrombotic microangiopathies. Therefore, a nephrologic consultation supposed the 
clinical diagnosis of a tubulointerstitial LEN-induced nephropathy without proteinuria. Patient never 
stopped/reduced LEN since December 2016 and concomitantly received corticosteroids (starting dose of 
prednisone was 40 mg/day), with progressive tapering according to renal function tests (serum creatinine 
and BUN). After one month of steroid dose adjustment, patient carried on fixed daily dose of prednisone 
12.5 mg/day with stabilization (within grade 1 or 2) of renal function in the following six months. On August 
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2017, a CT-scan showed a PD in the liver according to RECIST 1.1 and LEN plus prednisone were definitely 
stopped. Because of persistent good performance status, chemo-refractory and slow-growing disease (with 
most tumor burden in the liver), two cycles of Trans-Arterial Chemo-Embolization (TACE) on the largest 
liver metastases were performed (in October and December 2017).Patient is still alive without any disease-
related symptoms and creatinine increase is still within grade 1. 
 
3 REVIEW 
 3.1 LENVATINIB-INDUCED RENAL FAILURE (LIRF) AND PROTEINURIA 
Data coming from the only LEN pivotal trials already published as full-papers [2] [3] showed a complex 
safety profile for this drug. As illustrated in Table 2, in both trials almost 100% and 75% of patients 
experienced at least one any-grade (AG) and grade 3 (G3) treatment-related adverse events (TRAE), 
respectively. This led to frequent drug discontinuations and/or dose reductions, thus impairing the LEN 
exposition and potentially patient outcomes. Indeed, a clear-cut relationship between drug exposure and 
anticancer activity has already been well described for multikinase inhibitors Sunitinib and Sorafenib. [10, 
11]. 
In the pivotal trial of LEN in RAI-refractory metastatic and progressive DTC (SELECT study) [2], proteinuria 
was one of the most frequent TRAEs, resulting as the second one (10%) among ≥G3 TRAEs (after  AH, 
41.8%) and the third cause (18.8%) of drug interruptions and/or reductions after diarrhea (22.6%) and  AH 
(19.9%). In a subgroup analysis of SELECT trial, including elderly patients (> 65 years) [11], a higher 
incidence of G3 TRAEs, especially including  AH and proteinuria, was reported in elderly (88.7%) versus 
younger (≤ 65 years) DTC patients (67.1%), thus leading to a shorter time (1.5 vs 3.7 months, respectively) 
elapsed before the first dose reduction.  
Proteinuria was the most frequent G3 TRAE when LEN has been studied as monotherapy in RCC patients 
(19%), compared to combination of LEN plus everolimus (4%) and everolimuns alone (2%) [3].  
In the phase II trial of LEN in HCC [12], proteinuria was the most frequent cause of study drug withdrawal 
(11%).  
Table 3 reported the incidence of AG and G3 LEN-induced renal failure (LIRF) and proteinuria in all studies 
actually published as full-papers.  
The percentage of ≥G3 proteinuria (10%) of overall SELECT population approximately doubled analyzing 
only  Japanese patients (20%) included in the same study [13] or considering different cancer settings, such 
as HCC (19.6%) [12] and RCC (19%) [3].  
The subgroup analysis of elderly (> 65 years) in SELECT trial [11] confirmed this trend for G3 proteinuria 
(13.2%) when compared to  that observed (7.7%) in younger patients (≤ 65 years).   
In addition to age, further pre-existing risk factors of RF induction were identified:  AH, stage≥3 chronic 
kidney disease (CKD),  TMA, and all grade proteinuria [14].  
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3.2 PATHOGENESIS 
3.2.1 HYPERTENSION AND PROTEINURIA 
Isolated AH is the most common adverse event observed with agents targeting the VEGF/VEGFRs. This side 
effect can be mediated by several mechanisms: reduction of cell renewal, apoptosis of endothelial cells, 
rarefaction of capillaries and arterioles, reduced production of vasodilators (e.g. nitric oxide and 
prostacyclin), direct vasoconstriction leading to peripheral resistance increase, and reduction of sodium 
renal excretion [15].  
On the other hand, proteinuria has a controversial pathogenesis. Taking into account that VEGF-A is 
expressed on podocytes, glomeruli and tubular cells, while VEGFRs on endothelial, mesangial and 
peritubular capillary cells, different mechanisms of proteinuria can be hypothesized [15]: dysregulation in 
repairing the early renal damage thus enhancing glomerulosclerosis; loss of selective glomerular 
permeability; increased intraglomerular pressure. The latter could also be secondary to AH. However, 
although there is a frequent association between proteinuria and AH,  it is not clear whether one is 
secondary to the other or both are independently caused by VEGF blockade. Proteinuria and AH are likely 
associated since patients with proteinuria develop hypertension more frequently. In contrast, AH does not 
seem to play a role in the pathogenesis of proteinuria, since the glomerular damage induced by reduced 
VEGF expression on podocytes has been demonstrated before the development of AH in animal knockout 
models [16].  
Starting from a phase I study, Keizer et al. structured a pharmacokinetic–pharmacodynamic model for AH 
and proteinuria. In this work they showed that both lenvatinib plasma concentration and an increased 
diastolic blood pressure have a separate effect on the development of proteinuria. [17] 
 
3.2.2 FGF/FGFR PATHWAY INHIBITION 
Other molecular targets could also explain LIRF. Among them, the FGF/FGFRs pathway blockade has to be 
cited, though controversial evidences are available; indeed, in vitro, FGF23 proved to exert divergent 
effects on fibroblast activation in cells derived from normal and obstructed kidneys. While FGF23 failed to 
stimulate fibrogenesis in normal fibroblasts, in those primed by injury, FGF23 induced pro-fibrotic signaling 
cascades via activation of TGF-β pathways. Tubule-derived FGF23 may thus amplify myofibroblast 
activation in acute renal injury, leading to renal fibrosis and injury [18].  
Having said that, because FGF/FGFR is not targeted by other antiangiogenic drugs, VEGF/VEGFR axis 
inhibition has to be considered the key mechanism in inducing RF.   
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4. CONCLUSION  
We described two cases of LIRF with alternative clinical and pathogenetic patterns. 
In both reports,  further causes of renal damage, such as concomitant nephrotoxic medications, co-existing 
autoimmune syndromes, infections and any other renal disorder, were excluded. 
In case 1, a glomerular drug injury with secondary proteinuria and indirect tubulointerstitial damage was 
observed and histologically characterized. Potentially, this represented a spurious (with only kidney 
disease) TMA-like pattern induced byVEGF/VEGFRs pathway inhibition. 
In case 2, the kidney damage was mainly based on a direct tubular failure, without proteinuria and 
glomerular involvement. A possible tubulointerstitial nephritis was clinically diagnosed. This hypothesis was 
also supported by the ex juvantibus effect yielded using corticosteroids. 
The putative pathogenetic mechanism presented in case 2 could open the way to a completely different 
diagnostic and therapeutic approach, based on chronic low-dose steroids use.  
 
5. EXPERT OPINION  
Acute or chronic renal function deficiency, regardless of its drug-related pathogenesis is based on a damage 
of renal tubuli. That is the reason why any primary glomerular injury, with secondary proteinuria, is rarely 
linked to RF, as it needs longer time to induce tubular alterations. This is the classical way throughout the 
most part of antiangiogenic agents, as LEN, might lead to renal disorders. Therefore, tubulointerstitial RF is 
underestimated compared to proteinuria [15]. Notably, in case 1, proteinuria needed almost four years to 
induce an acute RF. Moreover, in the literature [8], Brose et al also described renal toxicities as the most 
frequent LEN AEs (after AH) among elderly (> 65 years) thyroid cancer patients.  
 The renal side effects from TKIs have already been described, and the first multicentric experiences of LIRF 
in DTC as well [2]. However, to the best of our knowledge, this work reports the histological features of LIRF 
for the first time. 
In case 1, mesangiolysis is very rare and usually lacking in primary glomerular nephropaties, except for 
those observed in diabetes and hemolytic uremic syndrome (both excluded in  our patient) or in case of 
some cytotoxic chemotherapy-induced kidney injury (e.g. Mitomycin-C) [19]. Concomitantly, LEN-induced 
endothelial alterations, notably hypertrophy, determine severe vascular injury,  configuring a TMA-like 
pattern, similarly to that observed in the kidney injury  caused by other antiangiogenics.   
In this drugs class, the classical histopathological picture is characterized by glomerular endotheliosis, focal 
segmental glomerulosclerosis (sometimes collapsing), various glomerulopathies, and most commonly TMA 
[20], with few cases of acute interstitial nephritis. 
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With regards to the medical treatment of TKIs induced proteinuria, no standardized guidelines are 
available. Nevertheless, many papers reported the activity of ACE inhibitors in this setting [21]. In fact, the 
rationale to use this drugs class is the prevention of both AH and cardiovascular events [22].In case 2, a 
direct tubulointerstitial damage, without glomerular involvement and proteinuria development, was 
hypothesized. This type of injury was described for almost all antiangiogenics (e.g. Bevacizumab, Sorafenib, 
Sunitinib [23]), but it has never been reported with LEN. 
The time needed to be elapsed before LIRF induction was significantly shorter in case 2 (14 months) than 
what observed in case 1 (42 months) due to the intrinsic LIRF mechanisms explained. However, in both 
reports, timing remains as one of the most important variables, together with the presence or not of 
proteinuria, to differentiate these two models of LIRF.  
The weakness of case 2 was the lack of the histological confirmation: all conclusions were based only on the 
clinical results (blood and urinary tests) and no kidney biopsy was performed to avoid patient an invasive 
diagnostic approach. Moreover, apart from interstitial nephritis, a relevant number of glomerular 
abnormalities, like glomerulosclerosis, can respond to corticosteroid therapy. Our diagnosis of interstitial 
nephritis may be also less consistent due to the absence of both eosinophiluria and eosinophilia in our 
patient. With these caveats, in case of LIRF without proteinuria, low doses of steroids shoud be considered 
in order to avoid kidney biopsy and carry on with an active anti-tumor agent. In fact, an inflammatory 
component is very likely in TKI-induced renal damage. 
Regardless of these limitations, the identification  of different pathogenetic LIRF mechanisms could have a 
key relevance in optimizing the diagnostic and therapeutic strategies. Indeed, for example in case of a LIRF 
pattern characterized by G2 proteinuria (24-hour urine), such as in case 1, one could speculate to 
temporarily stop and reduce LEN after recovery from toxicity. This could be suggested because proteinuria 
tends to resolve with drug  withdrawal. For this reason, proteinuria should be always assessed in patients 
under treatment with LEN and the management of LEN-induced proteinuria could be the same of that 
caused by bevacizumab [24]. 
On the other hand, an acute kidney injury secondary to a possible interstitial nephritis could often lead to 
treatment discontinuation due to its trend to a rapid relapse, as demonstrated in case 2. In this alternative 
LIRF model, patients can benefit of chronic low-dose steroids without any drug interruption and/or dose 
reduction. The latter aspect is particularly relevant to optimize drug exposition.   
Therefore, it is intuitive that better understanding LIRF mechanisms may lead to a such promptness in 
discovering or preventing RF, thus improving drug efficacy and safety. Notably, saving toxicities deserves to 
be considered in long-term survivor cancer patients, like those here reported.     
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Abbreviation Meaning 
ACC Adenoid Cystic Carcinoma 
ACE Angiotensin Converting Enzyme 
AE Adverse Event 
AH Arterial Hypertension 
AJCC American Joint Committee on Cancer 
ATC Anaplastic Thyroid Cancer 
BUN Blood Urea Nitrogen 
CKD Chronic Kidney Disease 
CT Computed Tomography 
CTCAE Common Toxicity Criteria for Adverse Event 
DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DOTATOC DOTA-octreotide 
DTC Differentiated Thyroid Cancer 
ECOG Eastern Cooperative Oncology Group 
EMA European Medicines Agency 
FDA Food and Drug Administration 
FDG Fluoro-Deoxy-Glucose 
FGF Fibroblast Growth Factor 
FGFR Fibroblast Growth Factor Receptor 
G1-G2-G3-G4-G5 Grade 1 - Grade 2 - Grade 3 - Grade 4 - Grade 5 
HCC HepatoCellular Carcinoma  
KIT KIT proto-oncogene 
LEN Lenvatinib 
LIRF Lenvatinib-Induced Renal Failure 
PD Progression of Disease 
PDGFR-α Platelet Derived Growth Factor Receptor Alpha 
PET Positron Emission Tomography 
PS Performance Status 
RAI RadioActive Iodine 
RCC Renal Cell Carcinoma 
RET RET proto-oncogene 
RF Renal Failure 
SD Stable Disease 
TACE Trans-Arterial Chemo-Embolization 
TKI Tyrosine Kinase Inhibitor 
TMA Thrombotic MicroAngiopathy  
TNM Tumor Node Metastasis staging system 
TRAE Treatment Related Adverse Event 
TSH Thyroid Stimulating Hormone 
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VEGF Vascular Endothelial Growth Factor 
VEGFR Vascular Endothelial Growth Factor Receptor 
WBS Whole Body Scan 
List of abbreviations used in the text 
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Figure Legends:  
 
Figure 1 – Overview of case 1 time dependent values of serum creatinine (mg/dl; black line), proteinuria at 
urine dipstick (semiquantitative measurements: 1+, 2+, 3+; grey columns), 24-hour proteinuria (g/24h; 
green triangles), and lenvatinib daily dose (mg; blue lines. White spaces correspond to drug interruptions). 
 
Figure 2 – PAS staining of a glomerulus with segmental mesangiolysis (*) and rare double contours (arrow) 
in capillary wall. PAS staining, OM 40x. 
 
Figure 3 – Electron microscopy of a glomerulus: podocyte foot process effacement (**) and 
subendothelial/intramembranous deposits (*). Electron microscopy, x12000 
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Recruitment Disease Phase Title NCT number 
Recruiting 
Thyroid cancer 
2 Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer NCT02726503 
3 A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China NCT02966093 
4 Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T) NCT02430714 
2 
A Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to 
Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting 
Dose, But Have a Better Safety Profile 
NCT02702388 
2 UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone NCT03139747 
4 Post-Marketing Surveillance of Lenvima in Korean Patients NCT02764554 
Recurrent Endometrial or 
Ovarian Cancer 1 Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer NCT02788708 
GastroEsophageal Cancer 2 
A Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 
Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or 
Subsequent Line Therapies 
NCT03321630 
Hepatocellular Carcinoma 1 A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma NCT03006926 
Osteosarcoma 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma NCT02432274 
Solid tumors 2 Eribulin and Lenvatinib in Advanced Solid Tumors NCT02640508 1/2 Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors NCT02501096 
Renal Cell Carcinoma 2 Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With RCC NCT03173560 3 Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced RCC NCT02811861 
Non Clear Cell Renal Cell 
Carcinoma (nccRCC) 2 
A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With 
Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received 
Any Chemotherapy for Advanced Disease 
NCT02915783 
Rectal Cancer 1 Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma NCT02935309 
Advanced 
Pheochromocytoma 2 
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That 
Cannot Be Removed by Surgery NCT03008369 
Neuroendocrine Tumors 2 Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors NCT02678780 
Breast Cancer 2 Phase II Study of Single Agent Lenvatinib NCT03168074 1/2 Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer NCT02562118 
Not yet 
recruiting 
Solid tumors 
1 Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor NCT03009292 
1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors NCT03245151 
1 Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor NCT03009292 
2 Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling NCT02846766 
Renal Cell Carcinoma 2 Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) NCT03324373 
Differentiated Thyroid 
Carcinoma 2 
Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot 
Be Removed by Surgery NCT02973997 
Table 1 – Summary of ongoing (recruiting and not yet recruiting patients) clinical trials evaluating lenvatinib in Oncology 
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 Schlumberger, NEJM 2015 
N = 261 
Motzer, Lancet Oncol 2015 
N = 52 
Any-grade TRAE (%) 97.3 94 
≥ G3 TRAE (%) 75.9 73 
Drug interruption (%) 82.4 25 
Dose reduction (%) 67.8 62 
TRAE, treatment-related adverse events 
Table 2 – Safety of lenvatinib in pivotal trials for advanced thyroid and renal cell cancers 
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Disease Reference N pts Initial daily dose  of lenvatinib 
Proteinuria Renal failure 
Any grade Grade≥3 Any grade Grade≥3 
RAI-DTC 
Schlumberger, NEJM 2015 261 24 mg 32.2% 10% 4.2% 1.9% 
Brose, JCO 2017 106 24 mg 
27.7% (≤65y) 
vs 
35.8% (>65y) 
7.7% (≤65y) 
vs 
13.2% (>65y) 
0% (≤65y) 
vs 
0.9% (> 65y) 
NS 
Kiyota, Cancer Sci 2015 30 24 mg 63% 20% NS NS 
Berdelou, Thyroid 2017 88 24 mg NS* NS* NS* NS* 
ATC Tahara, Front Oncol 2017 17 24 mg 59% 6% NS NS 
RCC Motzer, Lancet Oncol 2015 52 24 mg 31% 19% NS NS 
HCC Ikeda, J Gastroenterol 2017 46 12 mg 60.9% 19.6% NS NS 
Table 3 – Incidence of any CTCAE grade and grade≥3 Lenvatinib-induced renal failure and proteinuria in Medical Oncology 
 
*Underestimated because of urine analysis was not done as routine test in study patients.   
 
Abbreviations (in alphabetical order): 
ATC, Anaplastic Thyroid Cancer. HCC, Hepatocellular Carcinoma. N pts, number of patients treated with lenvatinib. NS, Not Specified. RAI-DTC, Iodine-131 
Refractory Differentiated Thyroid Cancer. RCC, Renal Cell Carcinoma. y, years.  
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Figure 1 
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Figure 2 
 
Figure 3 
 
 
 
